215 related articles for article (PubMed ID: 11051256)
21. Clinical significance of p53 in non-small-cell lung cancer.
Komiya T; Hirashima T; Kawase I
Oncol Rep; 1999; 6(1):19-28. PubMed ID: 9864395
[TBL] [Abstract][Full Text] [Related]
22. Deregulated p21(WAF1) overexpression impacts survival of surgically resected esophageal squamous cell carcinoma patients.
Goan YG; Hsu HK; Chang HC; Chou YP; Chiang KH; Cheng JT
Ann Thorac Surg; 2005 Sep; 80(3):1007-16. PubMed ID: 16122475
[TBL] [Abstract][Full Text] [Related]
23. Structural alteration of p53 protein in patients with muscle invasive bladder transitional cell carcinoma.
Tiguert R; Bianco FJ; Oskanian P; Li Y; Grignon DJ; Wood DP; Pontes JE; Sarkar FH
J Urol; 2001 Dec; 166(6):2155-60. PubMed ID: 11696726
[TBL] [Abstract][Full Text] [Related]
24. Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma.
Chang SC; Lin JK; Lin TC; Liang WY
Int J Oncol; 2005 Jan; 26(1):65-75. PubMed ID: 15586226
[TBL] [Abstract][Full Text] [Related]
25. Expression of the p53 family in lung cancer.
Uramoto H; Sugio K; Oyama T; Nakata S; Ono K; Nozoe T; Yasumoto K
Anticancer Res; 2006; 26(3A):1785-90. PubMed ID: 16827107
[TBL] [Abstract][Full Text] [Related]
26. Mutational spectra of p53 in geographically localized esophageal squamous cell carcinoma groups in China.
Cao W; Chen X; Dai H; Wang H; Shen B; Chu D; McAfee T; Zhang ZF
Cancer; 2004 Aug; 101(4):834-44. PubMed ID: 15305417
[TBL] [Abstract][Full Text] [Related]
27. Expression and alteration of ras and p53 proteins in patients with lung carcinoma accompanied by idiopathic pulmonary fibrosis.
Takahashi T; Munakata M; Ohtsuka Y; Nisihara H; Nasuhara Y; Kamachi-Satoh A; Dosaka-Akita H; Homma Y; Kawakami Y
Cancer; 2002 Aug; 95(3):624-33. PubMed ID: 12209756
[TBL] [Abstract][Full Text] [Related]
28. Prognostic impact of p53 protein overexpression in patients with node-negative lung adenocarcinoma.
Suzuki H; Kawaguchi T; Hasegawa T; Yonechi A; Ohsugi J; Higuchi M; Yamada F; Shio Y; Fujiu K; Kanno R; Ohishi A; Gotoh M
Cancer Lett; 2006 Jun; 237(2):242-7. PubMed ID: 16102896
[TBL] [Abstract][Full Text] [Related]
29. Vascular endothelial growth factor, p53, Rb, Bcl-2 expression and response to chemotherapy in advanced non-small cell lung cancer.
Ludovini V; Gregorc V; Pistola L; Mihaylova Z; Floriani I; Darwish S; Stracci F; Tofanetti FR; Ferraldeschi M; Di Carlo L; Ragusa M; Daddi G; Tonato M
Lung Cancer; 2004 Oct; 46(1):77-85. PubMed ID: 15364135
[TBL] [Abstract][Full Text] [Related]
30. Interleukin-8 in non-small cell lung carcinoma: relation with angiogenic pattern and p53 alterations.
Boldrini L; Gisfredi S; Ursino S; Lucchi M; Mussi A; Basolo F; Pingitore R; Fontanini G
Lung Cancer; 2005 Dec; 50(3):309-17. PubMed ID: 16125276
[TBL] [Abstract][Full Text] [Related]
31. Topoisomerase IIalpha gene expression is regulated by the p53 tumor suppressor gene in nonsmall cell lung carcinoma patients.
Liu D; Huang CL; Kameyama K; Hayashi E; Yamauchi A; Sumitomo S; Yokomise H
Cancer; 2002 Apr; 94(8):2239-47. PubMed ID: 12001123
[TBL] [Abstract][Full Text] [Related]
32. Aneuploidy and prognosis of non-small-cell lung cancer: a meta-analysis of published data.
Choma D; Daurès JP; Quantin X; Pujol JL
Br J Cancer; 2001 Jul; 85(1):14-22. PubMed ID: 11437396
[TBL] [Abstract][Full Text] [Related]
33. p53 mutation is infrequent in clear cell carcinoma of the ovary.
Ho ES; Lai CR; Hsieh YT; Chen JT; Lin AJ; Hung MH; Liu FS
Gynecol Oncol; 2001 Feb; 80(2):189-93. PubMed ID: 11161858
[TBL] [Abstract][Full Text] [Related]
34. Potential increase in the prognostic value of p53 mutation by Pro72 allele in stage I non-small-cell lung cancer.
Chien WP; Wong RH; Wu TC; Cheng YW; Chen CY; Lee H
Ann Surg Oncol; 2009 Jul; 16(7):1918-24. PubMed ID: 19434453
[TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of expression of p53 oncoprotein in primary (stage I-IIIa) non-small cell lung cancer.
Tan DF; Li Q; Rammath N; Beck A; Wiseman S; Anderson T; al-Salameh A; Brooks J; Bepler G
Anticancer Res; 2003; 23(2C):1665-72. PubMed ID: 12820438
[TBL] [Abstract][Full Text] [Related]
36. Expression of MDA-7/IL-24 and its clinical significance in resected non-small cell lung cancer.
Ishikawa S; Nakagawa T; Miyahara R; Kawano Y; Takenaka K; Yanagihara K; Otake Y; Katakura H; Wada H; Tanaka F
Clin Cancer Res; 2005 Feb; 11(3):1198-202. PubMed ID: 15709189
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of p53 status in non-small cell lung cancer in correlation with postoperative adjuvant therapy.
Hanaoka N; Tanaka F; Wada H
Thorac Cardiovasc Surg; 2002 Dec; 50(6):355-9. PubMed ID: 12457313
[TBL] [Abstract][Full Text] [Related]
38. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
[TBL] [Abstract][Full Text] [Related]
39. Alterations in novel candidate tumor suppressor genes, ING1 and ING2 in human lung cancer.
Okano T; Gemma A; Hosoya Y; Hosomi Y; Nara M; Kokubo Y; Yoshimura A; Shibuya M; Nagashima M; Harris CC; Kudoh S
Oncol Rep; 2006 Mar; 15(3):545-9. PubMed ID: 16465410
[TBL] [Abstract][Full Text] [Related]
40. p16(INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer.
Kim DH; Nelson HH; Wiencke JK; Zheng S; Christiani DC; Wain JC; Mark EJ; Kelsey KT
Cancer Res; 2001 Apr; 61(8):3419-24. PubMed ID: 11309302
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
